Please wait





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage listed in row 11 is calculated based on 38,720,196 shares of Common Stock outstanding on December 18, 2025, as disclosed to the Reporting Persons by the Issuer.


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage listed in row 11 is calculated based on 38,720,196 shares of Common Stock outstanding on December 18, 2025, as disclosed to the Reporting Persons by the Issuer.


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage listed in row 11 is calculated based on 38,720,196 shares of Common Stock outstanding on December 18, 2025, as disclosed to the Reporting Persons by the Issuer.


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage listed in row 11 is calculated based on 38,720,196 shares of Common Stock outstanding on December 18, 2025, as disclosed to the Reporting Persons by the Issuer.


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage listed in row 11 is calculated based on 38,720,196 shares of Common Stock outstanding on December 18, 2025, as disclosed to the Reporting Persons by the Issuer.


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage listed in row 11 is calculated based on 38,720,196 shares of Common Stock outstanding on December 18, 2025, as disclosed to the Reporting Persons by the Issuer.


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage listed in row 11 is calculated based on 38,720,196 shares of Common Stock outstanding on December 18, 2025, as disclosed to the Reporting Persons by the Issuer.


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage listed in row 11 is calculated based on 38,720,196 shares of Common Stock outstanding on December 18, 2025, as disclosed to the Reporting Persons by the Issuer.


SCHEDULE 13G




Comment for Type of Reporting Person:  The percentage listed in row 11 is calculated based on 38,720,196 shares of Common Stock outstanding on December 18, 2025, as disclosed to the Reporting Persons by the Issuer.


SCHEDULE 13G



 
Frazier Life Sciences Public Fund, L.P.
 
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
Date:12/19/2025
 
FHMLSP, L.P.
 
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.
Date:12/19/2025
 
FHMLSP, L.L.C.
 
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, CFO of FHMLSP, L.L.C.
Date:12/19/2025
 
Frazier Life Sciences XI, L.P.
 
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.
Date:12/19/2025
 
FHMLS XI, L.P.
 
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.
Date:12/19/2025
 
FHMLS XI, L.L.C.
 
Signature:/s/ Steve R. Bailey
Name/Title:By Steve R. Bailey, CFO of FHMLS XI, L.L.C.
Date:12/19/2025
 
Frazier Life Sciences XII, L.P.
 
Signature:/s/ Gordon Empey
Name/Title:By Gordon Empey, General Counsel of FHMLS XII, L.L.C., GP of FHMLS XII, L.P., GP of Frazier Life Sciences XII, L.P.
Date:12/19/2025
 
FHMLS XII, L.P.
 
Signature:/s/ Gordon Empey
Name/Title:By Gordon Empey, General Counsel of FHMLS XII, L.L.C., GP of FHMLS XII, L.P.
Date:12/19/2025
 
FHMLS XII, L.L.C.
 
Signature:/s/ Gordon Empey
Name/Title:By Gordon Empey, General Counsel of FHMLS XII, L.L.C.
Date:12/19/2025
Exhibit Information

Exhibit 99.1 Joint Filing Agreement